Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis by Liu, Rong et al.
RESEARCH Open Access
Efficacy of praziquantel and artemisinin
derivatives for the treatment and prevention of
human schistosomiasis: a systematic review and
meta-analysis
Rong Liu
1*, Hui-Fen Dong
1, Yi Guo
2, Qin-Ping Zhao
1 and Ming-Sen Jiang
1*
Abstract
Background: Praziquantel has been used as first-line drug for chemotherapy of schistosomiasis since 1984. Besides
praziquantel, artemether and artesunate have also been used for the control of this infectious disease since late
1990s. In this article, we conducted a systematic review and meta-analysis to evaluate the antischistosomal efficacy
of different medication strategies including monotherapy or combination therapies of these drugs.
Results: A number of 52 trials from 38 articles published in peer-reviewed journals before July 2011 were selected
for analysis after searching the following literature databases: the Cochrane Library, PubMed/Medline, ISI Web of
Science, Chinese Biomedicine Literature Database, and China National Knowledge Infrastructure. Our meta-analyses
showed that a dosage of 30-60 mg/kg praziquantel compared with placebo produced a protection rate of about
76% (95% CI: 67%-83%) for treating human schistosomiasis, which varied from 70% to 76% with no significant
differences among the subspecies S. haematobium, S. japonicum or S. mansoni. Protection rates were higher when
praziquantel doses were elevated, as concluded from the nRCTs results: the protection rate of praziquantel at 40
mg/kg was 52% (95% CI: 49%-55%), and it increased to 91% (95% CI: 88%-92%) when the dosages were elevated
to 60/80/100 mg/kg divided two or more doses. Multiple doses of artemether or artesunate over 1- or 2-week
intervals resulted in protection rates of 65% to 97% for preventing schistosomiasis, and increased doses and shorter
medication intervals improved their efficacies. Praziquantel and artemisinin derivatives (artemether or artesunate) in
combination resulted in a higher protection rate of 84% (95% CI: 64%-91%) than praziquantel monotherapy for
treatment. praziquantel and artesunate in combination had a great protection rate of 96% (95% CI: 78%-99%) for
preventing schistosomes infection.
Conclusions: According to the results, praziquantel remains effective in schistosomiasis treatment, and multiple
doses would improve its efficacy; meanwhile, praziquantel is also a good drug for preventing acute schistosomiasis
morbidity. It’s better to use multiple doses of artemether or artesunate with 1- or 2-week intervals for prevention
against schistosome infection. Praziquantel and artemether or artesunate in combination perform better in
treatment than praziquantel monotherapy, and they are especially suitable for treating the patients with repeated
exposure to infected water.
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Schistosomiasis, an infectious disease caused by parasitic
trematodes (schistosomes) dwelling in the host’s mesen-
teric portal system, is a great public health problem in
tropical and subtropical regions. The disease causes
health and labor loss, and finally a significant reduction
in socioeconomic benefits. Approximately 207 million
people (more than 97% in Africa) are infected, and 779
million (85% in Africa) are at risk of being infected in
76 endemic countries worldwide, leading to the loss of
about 4.5 million disability-adjusted life years (DALYs)
[1-4]. Thus schistosomiasis control remains a challenge
in endemic regions [4-7].
There are five schistosome species parasitizing in
humans: Schistosoma japonicum, S. mansoni, S. haemato-
bium, S. mekongi,a n dS. intercalatum. S. japonicum is
transmitted by the amphibian snail Oncomelania and
causes intestinal and hepatosplenic schistosomiasis in the
People’s Republic of China, Philippines, and Indonesia; S.
mansoni, transmitted by Biomphalaria snails, causes
intestinal and hepatic schistosomiasis in Africa, the Ara-
bian peninsula, and South America; S. haematobium,
transmitted by Bulinus snails, causes urinary schistosomia-
sis in Africa and the Arabian peninsula. S. mekongi and S.
intercalatum are only of local importance [1-3,8,9].
In the mid-1980s, the WHO recommended schistoso-
miasis control strategies for humans by focusing on the
large-scale population-based and repeated chemother-
apy, which is still the key strategy today [10]. The che-
motherapy for human schistosomiasis is to take
antischistosomal drugs for prevention of morbidity in
high-risk population (i.e. chemoprophylaxis by prevent-
ing the young schistosomes - schistosomula developing
into adult egg-laying worms or killing them), and for
treatment of patients by eliminating adult worms, whose
eggs deposited in human tissue (e.g. liver and intestinal
wall) and caused pathogenesis. For schistosomiasis treat-
ment three drugs have been used, which differ in their
effects on schistosome species: metrifonate (targeting S.
haematobium), oxamniquine (targeting S. mansoni), and
praziquantel (PZQ) (for all human species). Due to its
broader spectrum, PZQ has finally become the first-line
medicine. In recent years, however, the potential resis-
tance problem of schistosomes to PZQ has come into
concern, which may necessitate searching for alterna-
tives [4,11-15]. Among those are artemether (AM) and
artesunate (AS), artemisinin derivatives (ARTs) with
anti-schistosomal potential which was first described in
the People’s Republic of China in the early 1980s. ARTs
were approved as schistosomiasis prevention drugs by
the Chinese Ministry of Health in 1996 [16]. They are
active against S. japonicum, S. mansoni and S. haemato-
bium, mainly targeting the immature, pre-adult stage,
the schistosomulum [17-21].
Only few publications, however, can be found with
comprehensive and statistical assessments of the efficacy
of these drugs controlling human schistosomiasis. To
get a more detailed overview on the efficacy of PZQ and
ARTs for human schistosomiasis treatment and preven-
tion, we collected a large group of studies published in
peer-reviewed journals, and conducted meta-analyses in
categories to assess their antischistosomal efficacy com-
prehensively, including single drug monotherapy and
drugs in combination against S. japonicum, S. mansoni,
S. haematobium and S. mekongi.
Methods
Search strategy and data sources
We conducted a computer-aided search of the literature
about anti-schistosomal efficacies assessments of PZQ,
A Ma n dA Su s e da l o n eo ri nc o m b i n a t i o nf o rh u m a n
schistosomiasis. Source databases were the Cochrane
Library (Issue 7, 2011), PubMed/Medline (1966 to July
2011), ISI Web of Science (1975 to July 2011), Chinese
Bio-Medicine Literature Database (CBM, 1979 to July
2011) and China National Knowledge Infrastructure
(CNKI, 1994 to July 2011). A review of European and
American “grey literature” databases (NTIS, SIGLE)
were also conducted. The terms and medical subject
headings (MeSH) used in retrieving citations were
“schistosom*” (* means the inclusion of all words with
the preceding radical), “praziquantel”, “artemisinin”,
“artemether”, “artesunate”, “chemotherapy”. The retrieval
formula was: schistosom* AND (praziquantel OR arte-
mether OR artesunate). The searches were performed
mainly in Chinese and English with a limitation to
human participants. One reviewer (LR) identified rele-
vant studies by screening titles and abstracts; a manual
search was performed systematically using the authors’
reference lists. The full-texts of potentially relevant stu-
dies were further evaluated by three reviewers (RL, HFD
and YG).
Criteria of inclusion and exclusion
The inclusion criteria were: (i) independent studies
assessing the antischistosomal efficacy of PZQ, AM and
AS, administrated alone or in combination for human
schistosomiasis treatment and prevention; (ii) the year
of the study conducted or published was reported; (iii)
the sample size was reported; (iv) the same drugs’ effi-
cacy evaluation indicators between experimental popula-
tions and control populations, i.e. reporting
parasitological outcome eggs-positive or eggs-negative
by Kato-Katz thick stool smears technique and/or mira-
cidia hatching tests for detecting eggs of S. japonicum,
S. mansoni, and S. mekongi or urine filtration for detect-
ing eggs of S.haematobium after approximately 3-4
weeks post-treatment, which was recommended as the
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diagnosis by WHO in 1980 [10]; or reporting emergence
or absence of acute schistosomiasis in the trials of asses-
sing some drug’s efficacy in controlling morbidity; (v)
the studies were either randomized controlled trials
(RCTs) or non-randomized control trials (nRCTs); (vi)
with raw data which could be changed into relative risk
(RR) and 95% CI RR and 95% CI were reported.
Exclusion criteria were: (i) study participants were not
human; (ii) without control group; (iii) incomplete infor-
mation; (iv) duplicate publications; (v) studies described
only results without detailed background and method
introduction; (vi) reviews. Figure 1 summarizes the stu-
dies selection process.
Data extraction and methodological/quality assessment
The following information was independently extracted
by two reviewers (RL and YG) and was checked
together, discrepancies were solved through discussion.
The extracted information included: first author’sn a m e
and year of publication, test sites (i.e. where trials were
implemented), time (i.e. when trials were implemented),
participants, schistosoma species, interventions, diagnos-
tics methods, follow-up time, raw dichotomous data of
efficacy assessment (NO. of positive/NO. of diagnosed),
RRs and their 95% CIs, type of study design (RCT or
nRCT), and intervention purposes (prevention or
treatment).
The quality of included RCTs was assessed by examin-
ing whether there is randomization, blinding, and infor-
mation about follow-up and dropouts/withdrawals of
participants according to the guidance of the methodo-
logical quality assessment of RCTs in the Cochrane
Handbook for Systematic Reviews of Interventions 4.2.6
and the Jadad scoring criteria [22,23]. The score for
quality scale ranges from 0 to 5 points, the higher the
s c o r e ,t h eh i g h e rt h eq u a l i t yo ft r i a l ;a n dat r i a lw i t ha
Jadad score ≥3 has been considered to be of ample
quality.
Diseases, interventions and outcomes
Schistosomiasis japonica, schistosomiasis mansoni, schis-
tosomiasis haematobia, and schistosomiasis mekongi
were included in this meta-analysis. The participants
included schoolchildren, villagers, schistosomiasis
patients, fishermen, and people or soldiers participating
in fighting against floods.
The participants of experimental groups took anti-
schistosomal drugs such as PZQ, AM, or AS alone or in
combination for treatment (to remove the adult worms
from schistosomiasis patients by PZQ) or prevention (to
control morbidity in high-risk population by ART or
PZQ). Control groups took the same dose of placebo or
PZQ (of the combination therapy trials) or nothing. The
chemotherapeutic outcome evaluation was parasitologi-
cal cure, which was defined as eggs-positive or eggs-
Figure 1 Flow diagram showing the articles selection process for present meta-analyses of the efficacy of PZQ and ART (AM and AS)
administrated alone or in combination for human schistosomiasis treatment or prevention. Individual searches don’t add up to 351
because some articles could be found simultaneously in multiple literature databases.
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miasis symptoms.
Data synthesis and statistical analysis
Meta-analyses were conducted in categories of PZQ,
AM, or AS alone and in combination, respectively. RRs
based on dichotomous data were set as statistical indica-
tors. Subgroup analyses were conducted according to
different design types, schistosoma species, time of medi-
cation and dosages. The protection rates were calculated
based on the summary RRs. All the statistical analysis
work was performed using the statistical package
Review Manager 4.3 software (Cochrane Collaboration,
Oxford, UK) and Stata/SE 11 (Stata
® Corporation,
Texas, USA) for Egger’s publication bias test by LR. The
fixed-effects model was used to combine study-specific
RRs, when there was no significant heterogeneity among
studies. Otherwise, the random-effects model was used.
Publication bias and sensitivity analysis
In order to examine the reliability and stability of our
meta-analyses, publication bias was assessed by means
of both funnel plot (qualitative) and Egger’s publication
bias test (quantitative). In addition, sensitivity analysis
was performed by excluding some trials with different
schistosome species (as the parasitological diagnosis
method used for S. haematobium is different from that
of other species) or with larger sample size.
Results
Studies selected
Overall, 38 articles with 52 trials met the inclusion cri-
teria and were finally used for this meta-analysis. Figure
1 shows the studies’ selection process: 19 trials on
PZQ’s efficacy evaluation (9 RCTs and 7 nRCTs on
treatment, 2 RCTs and 1 nRCT on prevention) [24-37];
12 RCTs on AM’s efficacy for prevention [38-49]; 16
RCTs on AS’s efficacy (14 RCTs for prevention and 2
RCTs for treatment) [24,30,50-59], 6 RCTs out of Zhang
et al.’s study [55] of AS’se f f i c a c yi np r e v e n t i n gS. japo-
nicum infections reported the duplications of studies
from Liu et al. [58], Yi et al. [56], Xu et al. [50,51], and
Liu et al. [57] and were excluded; one RCT on PZQ and
AM in combination for treatment [60]; 3 RCTs on PZQ
and AS in combination (2 RCTs for treatment and one
for prevention) [24,30,61]. A number of 5 studies con-
tained 2 or more independent trials [34,35,37,38,55].
Further 5 studies [62-66] were excluded for duplicate
publication, and 3 studies for different design types
[67-69].
Study characteristics and methodological quality
Studies were conducted in areas that are endemic for
human schistosomiasis, including Nigeria, Burkina Faso,
Niger, KwaZulu/Natal of South Africa, Côte d’Ivoire,
Gabon, Philippines, Tanzania, Brazil, and China (see
Additional file 1, Table S1). PZQ dosages applied ranged
from a single oral dose of 30-60 mg/kg or divided (2-3)
dosages in RCTs-designed studies, and only one trial
reported about participants who had received a single
oral dose of PZQ at 20 mg/kg [35]. For nRCTs about
PZQ’s efficacy, there were several types of drug adminis-
tration i.e. a single oral dose of 40 mg/kg or 60 mg/kg,
multiple (2-3) oral doses of the same concentrations,
two doses of 40 mg/kg, and two doses of 30 mg/kg
added by another dose of 40 mg/kg. The dosage of AM
given was 6 mg/kg/day, ranging from 2 doses to 13
doses over about 15-day intervals, 3-week intervals, or
one-month interval, for preventing schistosomiasis mor-
bidity. AS was applied by two medication types, 4 mg/
kg/day over 3 consecutive days for treatment, or 3-14
doses of 6 mg/kg/day over 1- or 2-weeks intervals for
prevention. For PZQ and AM in combination partici-
pants of the experimental group received a single oral
dose of 60 mg/kg PZQ and 6 mg/kg/day AM [60]; for
PZQ and AS in combination for treating schistosomiasis
haematobia, participants received a single oral dose of
40 mg/kg PZQ and a dose of 4 mg/kg/day AS [24,29].
Participants in the control groups received just a single
oral dose of 40 or 60 mg/kg PZQ and AM placebo or
AS placebo. In another study with PZQ and AS in com-
bination to treat schistosomiasis japonica by soldiers
participating in fighting against floods, participants of
the experimental group received 1200 mg PZQ once
divided into two doses and AS 300 mg once for every 7
days, participants in the control group received nothing
[61]. The follow-up time post-treatment differed from
studies ranging from 2 weeks to more than 2 years,
most of which ranged from 4 weeks to half a year.
Table 1 summarizes the Jadad scores of the included
RCTs. Among the 29 RCT-designed studies, only 5 stu-
dies [29,40,41,43,51] have described the randomization
method; one study [37] did not include blinded alloca-
tion or outcome measurements, and 11 studies
[24,38,43,49,51-55,57,58] had no description of withdra-
wals or dropouts. Thus 28 of the included RCTs were
rated as providing good methodological quality based on
a Jadad score of 3-5, and only one study [37] had a
Jadad score of 2. The nRCTs without quality assessment
were analyzed separately from the RCTs.
Meta-analysis
Compared to results using a placebo, a single dose of
30-60 mg/kg PZQ provided a protection rate of 76%
(95% CI: 67%-83%) for treatment of schistosomiasis
japonica, which was higher as point estimation than its
protection rate against schistosomiasis haematobia [72%
(95% CI: 65%-78%)] or schistosomiasis mansoni [70%
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rates among the three species are of no statistical signifi-
cance with regard to their 95% CIs, and their overall
pooled protection rate is 73% (95% CI: 67%-78%); mean-
while, the increasing dosage within 30-60 mg/kg gives
no significant improvement in efficacy. Compared to
this, 20 mg/kg PZQ seems to be less effective resulting
in a protection rate of just 16% (95% CI: -81%-61%). For
PZQ’s efficacy during nRCTs, dosages of 60-100 mg/kg
(i.e. 60/(40 × 2 doses)/(30 × 2 doses + 40) mg/kg) pro-
vide better efficacies than a single dose at 40 mg/kg,
their protection rates were 91% (95% CI: 88%-92%) vs.
52% (95% CI: 49%-55%), respectively. In addition, several
doses of PZQ at 40 mg/kg of both two RCTs and one
nRCT produced great effects on preventing schistoso-
miasis morbidity, their protection rates were 98% (95%
CI: 93%-99%) and 100%, respectively. Multiple (6-7)
doses of 6 mg/kg AM appliedi n1 - m o n t hi n t e r v a l s
resulted in protection rates of 24% (95% CI: 8%-37%) with
respect to preventing S. japonicum infections, which
increased to 50% (95% CI: 29%-65%) when the time inter-
val was shortened to 3-week intervals; 4-7 doses of 6 mg/
kg AM applied in 15-day intervals led to protection rates
of 65% (95% CI: 50%-76%) in preventing S. japonicum
infections, which increased significantly to 90% (95% CI:
79%-95%) when the dosages were increased to 8-13 doses.
In addition, 2-3 doses of 6 mg/kg AM with 15-day inter-
vals produced great effects on preventing against S. japoni-
cum infection in persons of short term exposure, who e.g.
participated in fighting against floods, here, the protection
rate was 91% (95% CI: 76%-97%). 3 doses of 6 mg/kg AS
given during 1-week intervals used to prevent S. japoni-
cum infection resulted in protection rates of 89% (95% CI:
55%-97%), which rose to 97% (95% CI: 88%-99%) when
the dosages increased to 8 doses; 3-5 doses of 6 mg/kg AS
applied in 2-week intervals used to prevent S. japonicum
Table 1 Assessment of methodological quality of the included RCTs by Jadad scoring criteria*
Trial Randomized† Double-blinded§ A description of withdrawals or dropouts Jadad score
Inyang-Etoh PC, 2009 1 2 0 3
Borrmann S, 2001 2 2 1 5
Santos AT, 1979 1 2 1 4
McMahon JE, 1979 1 1 1 3
Katz N, 1979 1 2 1 4
Liu ZG, 1997 1 0 1 2
Song Y, 2006 1 2 0 3
Li YS, 2005 1 2 1 4
N’Goran EK, 2003 2 2 1 5
Utzinger J, 2000 2 2 1 5
Tian ZY, 1999 2 2 0 4
Huang AS, 1999 1 2 1 4
Song Y, 1998 1 2 1 4
Xu MS, 1997 1 2 1 4
Tian ZY, 1997 1 2 1 4
Wang JL, 1997 1 2 1 4
Xiao SH, 1996 1 2 0 3
Xiao SH, 1995 1 2 1 4
Xu MS, 2001 1 2 0 3
Cui JF, 2001 1 2 0 3
Sun MX, 2000 1 2 0 3
Zhang SJ, 2000 1 2 0 3
Yi ZH, 2000 1 2 1 4
Liu HY, 1999 1 2 0 3
Xu MS, 1998 2 2 0 4
Liu ZD, 1996 1 2 0 3
Xu MS, 1996 1 2 1 4
Wu LJ, 1995 1 2 1 4
Hou XY, 2008 1 2 1 4
* Range 0~5 (the higher the Jadad score is, the higher the quality of study is).
† Represents generation of allocation sequence.
§ Represents allocation concealment.
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84%), which rose significantly to 95% (95% CI: 91%-97%)
when the dosages increased to 8-14 applications. Two stu-
dies showed no significant effects of AS treatments com-
pared to a placebo, with a protection rate of 45% (95% CI:
-78%-83%) which spanned across zero. PZQ and ART
(AM or AS) in combination used for schistosomiasis treat-
ment resulted in a better efficacy than PZQ treatment
alone, with a pooled RR of 0.61 (95% CI: 0.39-0.96) and a
protection rate of 39% (95% CI: 4%-61%), which was con-
verted to 84% (95% CI: 64%-91%) after the control PZQ
was transformed into placebo based on the RCTs’ result of
PZQ at 30-60 mg/kg for treatment. PZQ and AS in com-
bination had a great effect on prevention against S. japoni-
cum infection with a protection rate of 96% (95% CI: 78%-
99%). All of these results are summarized in detail in Fig-
ure 2, 3, 4 and 5 and Table 2.
Publication bias and sensitivity analysis
Funnel plots and Egger’s test results of publication bias
estimation of each subgroup based on study-specific
R R ss h o w e dt h a ti nm o s ts u b g r o u p st h ei n c l u d e dt r i a l s
are almost evenly distributed around the vertical axis of
pooled RR and within the 95% CI of pooled log RR (Fig-
ures 6,7, 8 and 9). This indicated that no evidence of a
publication bias exists, except for the subgroup RCTs-
designed of 8-13 doses of 6 mg/kg AM during 15 day-
intervals used for prevention against S. japonicum infec-
tion. The P value of Egger’s test was 0.01, which indi-
cated that a publication bias may exist. In addition,
sensitivity analyses indicated there were no significant
c h a n g e si nt h er e s u l t so fR R s ’ estimation and their 95%
CIs between the restricted data sets and their combined
overall values in each subgroup (Table 3). Thus the
results of our meta-analyses are stable and credible.
Adverse effects
Adverse effects were reported for people who had taken
PZQ for treatment or prevention against schistosomia-
sis. Among those were dizziness, stomach discomfort or
stomach ache, headache, nausea, debility, muscular and
joint soreness, and diarrhoea, which disappeared shortly
after drug withdrawal [70,71]. In the trials of Tian et al.
[42], Song et al. [38,45], Xu et al. [46], Wang et al. [47]
Figure 2 Forest plots showing the efficacy of PZQ (30-60 mg/kg) for schistosomiasis treatment (RCTs).n / N=n u m b e re x a m i n e da s
positive outcome (or not cured) over number of participants who were examined. Sub-groups with trials with patients infected by different
Schistosoma species (01: S. haematobium, 02: S. mansoni, and 03: S. japonicum) were separately combined. The P value of each test for
heterogeneity was ≥0.05, thus the fixed-effect model was used to combine trial-specific RRs of each sub-group and the total pooled RR, and its
95% CI were calculated by combing all sub-groups. No statistically significant difference among pooled RRs of sub-groups about different
species was observed.
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AM in preventing against S. japonicum in the regions of
Anhui, Hunan, Jiangxi and Yunnan provinces, only a
few of total 4, 754 participants aged from 5 to 60 years
old experienced symptoms of mild and transient dizzi-
ness, headache, and abdominal pain symptoms with
good tolerance and less severe adverse effects [72,73].
AS was also reported being well tolerable. Only about
1% of the participants reported about mild abdominal
pain, dizziness, headache and diarrhoea, or slight fever
[59].
Discussion
PZQ was synthesized by Bayer and Merck in Germany
in 1972 [74], and introduced for clinical use in the
People’s Republic of China since 1978 [74,75]. Today,
PZQ is the most frequently used drug for schistosomia-
sis treatment in endemic areas, and regularly used also
in large scale programmes [76]. PZQ exhibits stage-spe-
cific functions in killing adult worms [73,77,78]. Our
meta-analysis showed that a single oral dose of 30-60
mg/kg PZQ or 40/60 mg/kg divided in two doses during
RCTs resulted in protection rates of 73% (95% CI: 67%-
78%) for treating schistosomiasis. No significant differ-
ences were observed among the species S. haematobium,
S. japonicum and S. mansoni, but the protective efficacy
decreases significantly to 16% (95% CI: -81%-61%) when
the PZQ dosage decreased to a single dose of 20 mg/kg.
Similarly, 60-100 mg/kg PZQ (i.e. 60 mg/kg as single or
double treatment, two doses of 40 mg/kg, or two doses
Figure 3 Forest plots showing the efficacy of AM using 6 mg/kg for preventing schistosome infection (RCTs). The trials were stratified
into sub-groups based on dosages and Schistosoma species. (01) 4-7 doses by 15-day intervals for preventing S. japonicum infection (pooled RR
was synthesized by the fixed-effect model); (02) 2-3 doses by 15-day intervals for preventing S. japonicum infection of short term exposure; (03)
8-13 doses by 15-day intervals for preventing S. japonicum infection (pooled RR was synthesized by random-effect model); (04) 6-7 doses by 3-
week intervals for preventing S. mansoni infection; (05) 6-7 doses by 1-month intervals for preventing schistosome infection - S. haematobium
and S. japonicum (pooled RR was synthesized by the fixed-effect model).
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Page 7 of 17Figure 4 Forest plots showing the efficacy of AS using 6 mg/kg for preventing S. japonicum infection (RCTs). The trials were stratified
into sub-groups based on different dosages and time intervals between every two adjacent doses. (01) 8 doses by 1-week intervals; (02) 3 doses
by 1-week intervals; (03) 8-14 doses by 2-week intervals; (04) 3-5 doses by 2-week intervals. The P values of test for heterogeneity of subgroups
01, 03 and 04 were >0.05 each, thus the pooled RRs were synthesized by the fixed-effect model.
Figure 5 Forest plots showing the efficacy of PZQ and ARTs (AM or AS) in combination for schistosomiasis treatment. (01) PZQ and AS
in combination for treating against S. haematobium or S. japonicum; (02) PZQ and AM in combination for treating against S. japonicum. The
pooled RR of 0.61 (95% CI: 0.39-0.96) was determined by combing the two subgroups as the P value of overall heterogeneity test was 0.62.
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Studies included Trials
(n)*
Participants
(N1/N2)
Δ
Pooled RRs
(95% CI)
▲
Protection rates
% (95% CI)
Heterogeneity
test, P values
PZQ for treatment 16 4108/5331§ -- -
￿ RCT designed (20 mg/kg) against S. mansoni 1 4/2 0.84 (0.39,
1.81)
16 (-81, 61) -
￿ RCT designed (30-60 mg/kg) 8 348/220 0.27 (0.22,
0.33)
73 (67, 78) 0.88
￿S. haematobium 5 220/164 0.28 (0.22,
0.35)
72 (65, 78) 0.70
￿S. mansoni 2 12/13 0.30 (0.12,
0.75)
70 (25, 88) 0.85
￿S. japonicum 1 116/43 0.24 (0.17,
0.33)
76 (67, 83) -
￿ nRCT designed (40 mg/kg) 3 2375/2847 0.48 (0.45,
0.51)
52 (49, 55) <0.01
￿ nRCT designed (60/(40 × 2)/(30 × 2 + 40) mg/kg) 4 1381/2262 0.09 (0.08,
0.12)
91 (88, 92) 0.17
PZQ for prevention against S. japonicum 3 2405/121 -- -
￿ RCT designed 2 155/61§ 0.02 (0.01,
0.07)
98 (93, 99) 0.15
￿ nRCT designed 1 2250/60 0.00 (0.00,
0.00)
100 -
AM for prevention (6 mg/kg) (RCTs) 13 4030/3771§ -- -
￿ 2-3 doses by 15-day interval against S. japonicum by short
term exposure during fighting against floods
1 202/212 0.09 (0.03,
0.24)
91 (76, 97) -
￿ 4-7 doses by 15-day interval against S. japonicum 3 713/706 0.35 (0.24,
0.50)
65 (50, 76) 0.65
￿ 8-13 doses by 15-day interval against S. japonicum 6 2429/2563 0.10 (0.05,
0.21)
90 (79, 95) <0.01
￿ 6-7 doses by 3-week interval against S. mansoni 1 128/140 0.50 (0.35,
0.71)
50 (29, 65) -
￿ 6-7 doses by 1-month interval against S. haematobium and S.
japonicum
2 558/737 0.76 (0.63,
0.92)
24 (8, 37) 0.88
AS (6 mg/kg) for preventing S. japonicum infection (RCTs) 14 5012/5241 -- -
￿ 3 doses by 1-week interval 1 168/200 0.11 (0.03,
0.45)
89 (55, 97) -
￿ 8 doses by 1-week interval 4 813/720 0.03 (0.01,
0.12)
97 (88, 99) 0.89
￿ 3-5 doses by 2-week interval 4 714/768 0.29 (0.16,
0.52)
71 (48, 84) 0.20
￿ 8-14 doses by 2-week interval 5 3317/3553 0.05 (0.03,
0.09)
95 (91, 97) 0.93
AS (4 mg/kg × 3 doses) for treating S. haematobia (RCTs) 2 132/74 0.55 (0.17,
1.78)
45 (-78, 83) <0.01
PZQ + AM/AS for treatment (RCTs) 4 227/234 0.61 (0.39,
0.96)
84 (64, 91) † 0.62
￿ PZQ + AM against S. japonicum 1 95/101 0.53 (0.10,
2.84)
86 (6, 98) † -
￿ PZQ + AS against S. haematobium 2 132/133 0.62 (0.38,
0.99)
83 (62, 92) † 0.33
PZQ + AS for prevention against S. japonicum (nRCT) 1 1362/112 0.04 (0.01,
0.22)
96 (78, 99) -
* There are 39 studies with53 trials included as some of the studies have multiple drugs trials.
Δ N1/N2= the number of participants in test group/the number of participants in control group.
▲ Pooled RRs (95% CI) are presented which were calculated by fixed-effects model when P value ≥0.05 of heterogeneity test, and by random-effects model if
not.
† Their average protection rates and 95% CI were calculated when the drugs given to the controls were transformed into placebo (based on the RCTs results of
PZQ 30-60 mg/kg for treatment).
§ The sum of participants in subgroups doesn’t equal the true total because some studies [35,39,64] have the same control participants.
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Page 9 of 17of 30 mg/kg adding a single dose of 40 mg/kg) during
nRCTs revealed protection rates of 91% (95% CI: 88%-
92%). The protective effect declined significantly to 52%
(95% CI: 49%-55%) when the dosage was reduced to a
single dose of 40 mg/kg. Thus it can be concluded that
multiple doses of 40/60 mg/kg PZQ provide an
enhanced efficacy in treating schistosomiasis compared
to a single dose. Additionally, when PZQ was applied
during the 3
rd-4
th week after the first exposure of a
patient to infected water harboring schistosome cercar-
iae, is turned out to be also effective in preventing acute
schistosomiasis morbidity with a protections rate of 98%
(95% CI: 93%-99%) in two RCTs, and 100% of one
nRCT [36,62]. Temporal observations and long-term fol-
low-up investigations about adverse effects showed that
PZQ had low toxicity, mild adverse symptoms, no mal-
formation effects, and no sequel. The incidence rates of
heavy side-effects were between 0.47% and 1.54% [79].
Thus PZQ has been a safe and effective antischistosomal
drug with a broad applicability for all species of schisto-
some [35,80].
O n ek e yi s s u eo fc h e m o t h e r a p yf o rh u m a ns c h i s t o s o -
miasis treatment is the concern of investigators and
clinicians for the emergence of PZQ resistance [81-83].
To date, there is no convincing clinical evidence for
schistosome resistance to PZQ used for human
Figure 6 Funnel plot and Egger’s publication bias test for RCTs of PZQ’s efficacy on schistosomiasis treatment. The pooled log-RR for
these trials is shown with a dashed vertical line, and the dashed slash lines distributed in both sides are the cutoff values of 95% CI of pooled
log RR. The Egger’s publication bias test showed that no publication bias exists (P = 0.96).
P=0.53
Figure 7 Funnel plot and Egger’s publication bias test for RCTs (2-7 doses by 15-day intervals) of AM’s efficacy on preventing S.
japonicum infection. There is one point (representing one trial) outside the cutoff values of 95% CI of pooled log RR. The Egger’s publication
bias test showed that no publication bias exists (P = 0.53).
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Page 10 of 17schistosomiasis treatment, although worrying low-cure
rates have been reported in some studies [84-93]. Our
meta-analysis covering a publication period from 1979
to 2009 indicated that PZQ is still effective for S. hae-
matobium, S. mansoni and S. japonicum with negligible
variations. We conclude that there is no reason to be
worried about the spreading of extensive and serious
PZQ resistance, which as King et al. mentioned in 2000
“... will likely take 10 or more years to emerge” [94].
However, one should not lose sight of first evidence for
reports indicating the existence of PZQ-tolerable
schistosomes which have emerged locally in some Afri-
can areas [90]. The observed variations between the
results of RCTs and nRCTs are explained by the slack
design of these nRCTs’. However, dose response trends
are the same in RCTs and nRCTs, i.e. larger dosage or
more treatment time points increase PZQ’s efficacy.
AM and AS, the derivatives of artemisinin (ART),
which was first extracted from the sweet wormwood
herb Artemisia annua by Chinese chemist Youyou Tu
and her team in 1970s, were at first used for the treat-
ment of malaria (http://www.laskerfoundation.org/
P=0.01
Figure 8 Funnel plot and Egger’s publication bias test for RCTs (8-13 doses in 15-day intervals) of AM’s efficacy on preventing S.
japonicum infection. There are two points (represented two trials) distributing outside the cutoff values of 95% CI of pooled log RR. The
Egger’s publication bias test showed that a publication bias may exist (P = 0.01).
P=0.18
Figure 9 Funnel plot and Egger’s publication bias test for RCTs of AS’s efficacy on preventing S. japonicum infection. The Egger’s
publication bias test showed that no publication bias exists (P = 0.18).
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Page 11 of 17awards/2011_c_description.htm); their potential against
S. japonicum was first reported in the 1980s [95,96], just
some years after the discovery of the antischistosomal
properties of artemisinin [97]. ARTs were approved as
antischistosomal drugs by the Chinese Ministry of
Health in 1990s [74]. AM and AS have similar functions
and kill larval worms (schistosomula) of different schis-
tosome species. Thus they have been used as chemopro-
phylactic drugs against schistosomes and could induce
resistance to reinfection [73,74,98]. Our meta-analyses
suggest that shortening application intervals could
improve their preventive potential. Best efficacies were
obtained with 8 or more doses of 6 mg/kg AM applied
with 15-day intervals ([90% (95% CI: 79%-95%]), or with
6 mg/kg AS applied with 1-week intervals (97% [95% CI:
88%-99%]). AS, however, showed poor performance with
respect to schistosomiasis treatment [24,29] (Table 2).
Thus AM and AS seem to be suitable as chemoprophy-
lactic drugs for preventing schistosomiasis morbidity,
but they seem not to be competent for treating schisto-
somiasis. In clinical studies using AM or AS to prevent
schistosomiasis incidence rates of less than 1% side-
effects were reported [71,74,99,100]. Up to now, there
haven’t been any reports about drug resistance of schis-
tosomes to these two drugs [101-103] besides one
exception. Hua et al [104] reported recently that the
sensitivity of artesunate against S. japonicum has
decreased after 10 years of use in China. The study
reported about protection rates obtained after the appli-
cation of 4 doses of 6 mg/kg AS given over 3-day inter-
vals between the 1
st and the 2
nd dose and the 3
rd and
the 4
th dose, A 11-day interval occurred between the 2
nd
and the 3
rd treatment. Surprisingly, the protection rate
during that time period was 74.8%, but it fell to 13.5%
when the AS application was changed to 4 doses of 6
mg/kg AS given in 1-week intervals. This unexpected
result is difficult to reconcile with similar study reports,
and because of its not-perfect study design and contra-
dictory statements between study design and drug
administration of participants, why it was not included
in our meta-analysis. Although the authors concluded
that they identified potential artemisinin-derivate-resis-
tance in S. japonicum, we believe, that more rigorous
research is needed to confirm this finding [105].
Our meta-analysis showed that PZQ and AS in combi-
nation provided similar preventive efficacy than those
obtained by AM or AS administrated as single drugs
(approximately 90%-97%). In conclusion, AM or AS
alone have the capacity as prophylactic drugs for schis-
tosomiasis prevention. PZQ and AM or AS in combina-
tion for treatment resulted in higher protection rates
(84% [95% CI: 64%-91%]) than PZQ alone (73% [95%
CI: 67%-78%]), respectively. Thus PZQ-ARTs combina-
tions are useful for schistosomiasis patients repeatedly
e x p o s e dt oi n f e c t e dw a t e r .I t ’sw e l lk n o w nt h a tA R T s
are used in large-scale programmes for malaria
Table 3 Sensitivity analysis of the efficacy of drugs targeting different species of schistosome (RCTs only)
Study Method* No. of
Trials
Participants (N1/
N2)
Pooled RRs (95%
CI)
Heterogeneity Test (P
)
A 8 348/220 0.27 (0.22, 0.33) 0.88
PZQ (RCTs) for treatment B 7 232/177 0.28 (0.22, 0.35) 0.90
C 6 336/207 0.27 (0.22, 0.32) 0.70
D 5 220/164 0.28 (0.22, 0.35) 0.70
AM for prevention (8-13 doses by 15-day interval) A 6 2429/2563 0.10 (0.05, 0.21) <0.01
E 5 1996/2111 0.12 (0.06, 0.24) <0.01
AS (6 mg/kg) 8 doses by 1-week interval for
preventing
A 4 813/720 0.03 (0.01, 0.12) 0.89
F 2 572/502 0.02 (0.00, 0.14) 0.73
AS (6 mg/kg) 8-14 doses by 2-week interval for
preventing
A 5 3317/3553 0.05 (0.03, 0.09) 0.93
G 4 879/893 0.04 (0.01, 0.14) 0.83
AS (6 mg/kg) 3-5 doses by 2-week interval for
preventing
A 4 714/768 0.29 (0.16, 0.52) 0.20
H 3 334/368 0.39 (0.20, 0.76) 0.39
*A: all trials were included in each subgroup, respectively.
B: one trial [34] with S. japonicum species was excluded.
C: two trials [36] with S. mansoni species were excluded.
D: three trials [34,36] were excluded, the remaining with S. haematoium.
E: one trial [47] in which there was zero person positive in the treatment group was excluded.
F: two trials from the same study [56] were excluded.
G: one trial [53] with the largest sample size was excluded.
H: one trial [52] with the largest sample size was excluded.
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resistant malarial parasites have been identified and con-
firmed in some areas [106-108]. Thus using ARTs for
schistosomiasis control is not advisable in areas where
schistosomiasis and malaria are co-endemic.
One limitation of this meta-analysis is that the diag-
nostic approaches used to determine parasites were dif-
ferent among the included trials. There were differences
between Kato-Katz techniquea n du r i n ef i l t r a t i o n ,t h e
number of specimens, and the number of examinations
between trials. The former cannot be changed because
it is determined by the two kinds of different clinical
pathogenesis. The latter can be improved through using
a standardized, quality-controlled diagnostic criterion
within and between trials. As discussed by Bergquist et
al. [109] and Danso-Appiah et al. [110], different diag-
nostic methods own different sensitivity and specificity,
and the same method also owns different sensitivity and
specificity for different infection levels and different
numbers of specimens, which were called the diagnostic
dilemmas. In the current meta-analyses, we tried to stra-
tify the included trials based on their diagnostic
approaches and the numbers of specimens and examina-
tions. However, we were restricted doing this since
many of the included trials didn’t report about the num-
bers of specimens and examinations for each participant.
Thus a unified study design is urgently needed to make
the study outcomes more comparable.
The results of the RCTs dealing with PZQ or ART
efficacies (using 40 mg/kg for treatment; 8-13 doses of 6
mg/kg AM with 15-day intervals for preventing, and AS
for treatment) have P values <0.05, which indicates that
the studies included in these three subgroups were het-
erogeneous. We presume that s o m ef a c t o r ss u c ha se . g .
regional variances, participants’ differences, or drug
dosage differences among these studies, may have con-
tributed to this heterogeneity [111]. RCTs are preferable
to be conducted when assessing drug efficacies in order
to exclude the influence of such variable factors. Differ-
ent species of schistosome were thought to have differ-
ent susceptibility to these drugs, and we stratified the
included trials and performed subgroup meta-analysis.
Interestingly, the results provided no hint in this direc-
tion when different species were used in RCTs using
PZQ (30-60 mg/kg for schistosomiasis treatment), AM
(6-7 doses of using 6 mg/kg in 1-month intervals for
preventing schistosomiasis), and PZQ + ART combina-
tory schistosomiasis treatment, in which the three schis-
tosome species S. haematobium, S. japonicum and S.
mansoni were studied (Figures 2, 3 and 5). We conclude
that these drugs may be equally effective against these
schistosome species, which we confirmed also by the
results of sensitivity analysis (Table 3).
Publication bias is usually cited as a reason for the
lack of validity in meta-analyses [112]. Publication bias
can occur when studies that found no significant effect
of antischistosomal drugs in schistosomiasis control are
less likely submitted and accepted for publication than
those with a positive result. The funnel plots of the
included trials showed no evidence for publication bias
except the subgroup of 8-13 doses of at 6 mg/kg AM
given with 15-day intervals for preventing schistosomia-
sis. Two points (represented two trials) were outside the
cutoff line, and the P value of Egger’s publication bias
test was 0.01, implying the existence of publication bias.
Additionally, we had found two Cochrane reviews dis-
cussing drugs for human schistosomiasis treatment
[113,114], one review examined PZQ, metrifonate and
artemisinin derivatives used alone or in combination for
treating urinary schistosomiasis, and the other assessed
the effects of oxamniquine and praziquantel on treat-
ment against S. mansoni. Thus our meta-analysis repre-
sents a good complementary data set adding to the
results obtained in these studies.
Conclusions
Facing the fact that an integrated strategy, which
emphasizes health education, access to clean water and
adequate sanitation, mechanization of agriculture, and
fencing of water buffaloes (mainly for schistosomiasis
japonica endemic areas), along with mass chemotherapy
for both human and livestock, have been suggested to
be carried out in parallel to control the infection sources
and to stop schistosome transmission [115-118], we
strived to conduct this meta-analysis hoping to provide
a scientific basis for monitoring and selecting antischis-
tosomal drugs efficiently, which is a crucial job for the
schistosomiasis integrated control programme. With
respect to the results obtained in our meta-analyses, we
recommend to use multiple doses of AM or AS at 6
mg/kg given in 1- or 2-week intervals for prevention
against schistosome infection during exposure to
infected water. PZQ remains effective in schistosomiasis
treatment, and multiple doses of PZQ at 30-60 mg/kg
can improve its efficacy. PZQ and AM or AS admini-
strated in combination are more effective than single
drug PZQ therapy, which maybe especially suitable for
the treatment of patients, who are repeatedly exposed to
infected water.
Additional material
Additional file 1: Table S1 Summary of the characteristics of the
included trials in our meta-analyses evaluating antischistosomal
drugs (PZQ, AM and AS), used alone or in combination, for human
schistosomiasis treatment or prevention. This table describes the
extracted characteristics of the included studies: Author, Year; Test sites;
Time; Participants; Species; Interventions; Diagnostic approach; Follow-up
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Usage.
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